|
ORF cDNA clones
|
CRISPR / TALEN
|
Lentivirus
|
AAV
|
TALE-TF
|
ORF knockin clones
|
|
Antibody
|
Proteins
|
miRNA target clones
|
qPCR primers
|
shRNA clones
|
miRNA products
|
Promoter clones
|
Validated All-in-One™ qPCR Primer for LGALS3(NM_002306.3) Search again
Product ID:
HQP010590
(click here to view gene annotation page)
Powered by BiozSpecies:
Human
Symbol:
Alias:
CBP35, GAL3, GALBP, GALIG, L31, LGALS2, MAC2
Gene Description:
galectin 3
Target Gene Accession:
NM_002306.3(click here to view gene page)
Estimated Delivery:
Approximately 1-3 weeks, but may vary. Please email sales@genecopoeia.com or call 301-762-0888 to confirm ETA.
Important Note:
By default, qPCR primer pairs are designed to measure the expression level of the splice variant (accession number) you selected for this gene WITHOUT consideration of other possible variants of this gene. If this gene has multiple variants, and you would like to measure the expression levels of one particular variant, multiple variants, or all variants, please contact us for a custom service project at inquiry@genecopoeia.com.
Validated result:
|
|
| A | B |
|
Each All-in-One™ qPCR Primer is experimentally validated to yield a single dissociation curve peak and to generate a single amplification of the correct size for the targeted gene. A cDNA Pool, containing reverse transcript products of 8 different human tissue total RNA(Liver, Testis,Muscle,Thyroid,Brain,Spleen,Stomach,Small Intestine)),was used as the qPCR validation template. qPCR was performed using 0.2 µM primer with 2XAll-in-One™ qPCR Mix (Catalog#: QP001,QP002,QP004,QP005). Reactions were incubated for 10min. at 95°C, followed by 40 cycles of 95°C for 10 sec.; 60°C, 20 sec. and 72°C, 15sec. using Bio-Rad iQ5™ Instrument. At the end of the last cycle, temperature was increased from 72 to 95°C to produce a melting curve. Panel A: Validated Result for Amplification Curve; Panel B: Validated Result for Melting Curve. |
|
Gene References into function
- These results demonstrate that galectin-3 phosphorylation regulates its anti-apoptotic signaling activity
- translocates to the perinuclear membranes and inhibits cytochrome c release from the mitochondria. A role for synexin in galectin-3 translocation.
- galectin-3 and CD26/DPPIV as preoperative diagnostic markers for thyroid nodules
- not a universal marker of malignancy in thyroid nodular disease in children and adolescents
- conclude that because of its location and affinity for gonococcal lipooligosaccharides (LOS) galectin-3 could play a role in gonococcal infection
- Galectin-3 expression is significantly stronger in metastatic lymph nodes and in poorly differentiated adenocarcinoma of stomach
- role in mediating MDA-MB-435 human breast carcinoma cell homo- and heterotypic adhesion under flow conditions
- role of galectin-3 on cyclin D(1) gene expression
- galectin 3 controls proliferation in thyroid cells
- downregulation of galectin-3 is associated with epithelial skin cancer
- Non-small-cell lung cancers examined were found to overexpress LGALS3 gene at levels three times higher than those of normal epithelial cells.
- Changes in the expressions of galectin-3 are potentially important for myeloid cell differentiation into specific lineages.
- Stable thyroid galectin- 3 transfectants acquired serum-independent growth, clonogenicity in soft agar, & loss of contact inhibition, indicating transformation of thyroid follicular cells by galectin-3 & possible involvement of galectin-3 in cell cycle.
- mechanism by which galectin-3 overexpression promoted cell death and PARP cleavage as well as caspase (-8, -9, and -3) activation during TRAIL treatment
- results demonstrate that galectin-3 mRNA may not be a suitable target for molecular-based diagnosis of thyroid carcinomas
- an additional marker of malignant potential of thyroid nodular lesions
- Galectin-3 has a role in activating Ras
- nuclear galectin-3 and TTF-1 have roles in progression of non-small cell lung carcinoma
- exerts opposite biological activities according to its cellular localization: nuclear galectin-3 plays antitumor functions and cytoplasmic galectin-3 promotes tumor progression
- A major circulating ligand for galectin-3, which is elevated in the sera of patients with colon cancer, is a cancer-associated glycoform of haptoglobin.
- The aim of this study was to investigate the potential of galectin-3 as a marker of malignancy in follicular patterned thyroid lesions
- expression is required for T. cruzi adhesion to human coronary artery smooth muscle cells and exogenous galectin-3 enhances this process, leading to parasite entry.
- Cultured galectin-3 deficient glioblastoma cells showed increased motility potential and modifications in cytoskeleton reorganization. Galectin-3 deficient cells have increased expression of proteins implicated in cell adhesion regulation.
- GALIG encodes a mitochondrial protein promoting cytochrome c release.
- Alterations in galectin-3 expression and distribution correlate with breast cancer progression
- Gal-3 and sFbg are two physiological mediators present at inflammatory sites that activate different components of the MAPK pathway and could be acting in concert to modulate the functionality and life span of neutrophils.
- Elevated expression of galectin-3 in the nuclei but not the cytoplasm may be an important biological parameter related to histological differentiation and vascular invasion in patients with ESCC.
- Expression of Gal-3 was higher in thin primary melanoma lesions than in benign pigmented skin lesions or metastases and seemed to correlate inversely with the aggressiveness.
- galectin-3 has a role in cancer apoptosis [review]
- Data give credence to the suggestion that gal-3 is a key regulator in the Wnt/beta-catenin signaling pathway and highlight the functional similarities between gal-3 and beta-catenin.
- Cytoplasmic-perinuclear gal-3 in majority of thyroid carcinomas and follicular adenomas(FA). Suggests involvement in thyroid tumorigenesis throughout antiapoptosis. In FA might anticipate evolution towards malignancy.
- The presence of galectin-3 in clinically silent microcarcinomas may indicate that galectin-3 is not related to growth or aggressiveness of papillary thyroid microcarcinomas but rather plays some other role in thyroid tumour biology.
- Gal-3 immunostaining is a valuable tool to support a diagnosis of PC in highly proliferating (Ki67 >6%) tumors affecting a single parathyroid gland.
- galectin-3 expression in adenoid cystic carcinoma; galectin-3 reactivity was significantly associated with regional and distant metastasis (P=0.045 and P<0.001, respectively)
- TFF-3 is commonly expressed in HCC and its expression correlates with tumor grade.
- Galectin-3 up-regulation of MUC2 transcription occurs at the level of transcription through AP-1 activation in colon cancer cells
- Galectin-3 is downregulated in cervical cancer tissues.
- Plasmid-encoding galectin-3 acts as a novel treatment for chronic asthma in mice producing nearly complete blockade of antigen responses with respect to eosinophil airway accumulation, airway hyperresponsiveness, and remodeling.
- a possible mechanism by which Tumor-associated antigen 90K may contribute to colon cancer progression is by modulating tumor cell adhesion to extracellular proteins, including galectin-3
- ANXA1 and Gal-3 changed in their content and localization when neutrophils adhere to endothelia. In contrast, a decrease in the total amounts of Gal-1 was detected in migrated compared to non-migrated neutrophils.
- siRNA knockdown of Galectin-3 inhibited myofibroblast activation after hepatic injury and may therefore provide an alternative therapeutic approach to the prevention and treatment of liver fibrosis
- Combined proteome-transcriptome-genome and functional analyses identify gal-3 as a candidate gene/protein in Type 1 diabetes. susceptibility
- Our results show a correlation between galectin-3 expression and apoptosis of tumor-associated lymphocytes.
- UBD protein allows the identification of LGALS3.
- An immunohistochemical panel consisting of HBME-1 and galectin-3 can make a correct distinction between malignant and hyperfunctioning thyroid neoplasms with high diagnostic accuracy.
- HIPK2 cooperates with p53 in Gal-3 repression and that this cooperation requires HIPK2 kinase activity.
- Galectin-3 modulates T cell activity and is reduced in the inflamed intestinal epithelium in inflammatory bowel disease
- Galectin-3 expressed in human monocytes is a receptor for the major xenoantigen Gal-alpha(1,3)Gal-beta(1,4)GlcNAc-R, expressed on porcine endothelial cells.
- Galectin-3 expression seems to be related to cell differentiation more than to tumor progression and prognosis in the neoplasms studied.
- Gal-3 is translocated to the nucleus, in part, via the importin-alpha/beta route and the Arg(224) amino acid residue of human Gal-3 is essential for its active nuclear translocation and its molecular stability
- galectin-3 lattices are robust and could, thus, be involved, as previously proposed, in the restriction of receptor clustering
- Galectin-3 interaction with Thomsen-Friedenreich disaccharide on cancer-associated MUC1 causes increased cancer cell endothelial adhesion
- the results presented here point to a key role for galectin-3 in CD13-mediated homotypic aggregation of monocytic cells.
- no association between LGALS3 T98P genotype and the phenotype of the benign or malignant thyroid tumor was observed.
- approach is validated through the observation of bound-state residual dipolar couplings for the disaccharide, lactose, bound to the carbohydrate recognition domain of the mammalian lectin, galectin-3
- GAL-3 mediates TRAIL signaling by regulating PTEN in human breast carcinoma cells
- this is the first report indicating that gal3 expression is regulated by promoter methylation in LNCaP cells and prostate tumors. The methylation of gal3 promoter may constitute a powerful tool for early diagnosis of prostate cancer.
- cytoplasmic and nuclear galectin-3 expression seem to be associated with activation of the Wnt-signaling pathway in well-differentiated thyroid neoplasms, suggesting that galectin-3 plays a role in thyroid carcinogenesis
- inhibition of both Wnt-2 and Gal-3 had synergistic effects on suppressing canonical Wnt signaling and inducing apoptosis, suggesting that aberrant canonical Wnt/beta-catenin signaling in colorectal cancer can be regulated at multiple levels
- galectin-3 demonstrates anti-apoptotic effects which contribute to cell survival in several types of cancer cells.
- gal-3 is a HIF-1-regulated lectin that plays an important role in nucleus pulposus cell survival.
- gal-3 immunodetection alone is not able to support the diagnosis of encapsulated follicular variants of papillary thyroid carcinoma.
- Results suggest that galectin-3 is a useful marker in the distinction between benign and malignant thyroid tumors.
- Finally, exogenous addition of galectin-3 into HUVECs induced angiogenesis in an APN-dependent manner.
- These findings indicate that MUC1 and galectin-3 function as part of a miR-322-dependent regulatory loop.
- Galectin-3 was without any significant correlation to the presence of metastases from thyroid papillary microcarcinoma.
- serum levels of Galectin 3 are increased in active Bhecet's disease
- decreased expression of Gal-3 to be substantially involved in the pathogenesis and further progression of prostate cancer specimens from benign prostate glands to a finally hormone-refractory malignant disease
- Detection of GAL3 improves the diagnosis in fine-needle biopsy with cytological findings suspicious for papillary thyroid carcinoma.
- Breast cancer cells harboring noncleavable galectin-3 show reduced tumor growth and angiogenesis compared with the wild-type.
- Our data suggest that Gal-3 is both a marker of atherosclerotic plaque progression and a central contributor to the pathology by amplification of key proinflammatory molecules.
- The average affinity of galectin-3 for serum glycoproteins was estimated to correspond to K(d) approximately 1-5 muM by modeling of the affinity chromatography and a fluorescence anisotropy
- Results indicate that galectin-3-induced apoptosis is regulated by cell surface expression of N-glycans and sialic acid in human diffuse large B cell lymphoma.
- Induces differential responses in T cells and neutrophils from Gal-1; is capable of inducing phosphatidylserine exposure with or without accompanying apoptosis in various leukocytes, providing a mechanism for galectin-mediated immunomodulation in vivo.
- Galectin-3 phosphorylation induced alterations in the far UV CD, indicative of an increase in ordered structure.
- Higher expression of galectin-3 was observed in bladder cancer tissue than in normal bladder tissue. We suggest the measurement of serum galectin-3 is useful for diagnosis of bladder cancer.
- gal-3 is differentially expressed in various brain tumors, and thereby, is a helpful biomarker in making differential diagnoses
- GAL-3 and pancreatic stellate cells are involved in the proliferation and infiltration process of pancreatic cancer cells
- Galectin 3 expression was significantly strong in thyroid tissue in thyroid cancer cases compared to non-cancer cases
- These data suggest a functional contribution of Runx-2-regulated galectin-3 expression to glial tumor malignancy.
- Distinct effects of splicing of two monoclonal antibodies directed against the amino-terminal domain of GAL3 are reported.
- Galectin-3 from papillary thyroid carcinoma was partially purified by affinity chromatography on lactose-agarose.
- Galectin-3 test proposed here does not replace conventional FNA cytology, but may be complementary diagnostic method for those follicular nodules that remain indeterminate.
- involved in the response of colon cancer cells to proinflammatory stimuli, such as the conditioned medium from activated macrophages
- DX-52-1 and HUK-921 inhibit a carbohydrate binding-independent function of galectin-3 that is involved in cell migration.
- Galectin-3 overexpression is more profound in early stages of papillary carcinoma, and its expression intensity decreases during tumor progression
- Galectin-3 up-regulation favors breast cancer progression and brain metastasis.
- Serum levels of galectins-1 and -3 are relatively high in patients with thyroid malignancy but there is considerable overlap in serum galectin-3 concentrations between those with benign and malignant nodular thyroid disease
- galectin-3 positivity is of little use in the differential diagnosis of sellar region tumors
- the coordinate up-regulation of gal-3 and ST6Gal-I, a feature that is characteristic of colon carcinoma, may confer tumor cells with a selective advantage by providing a mechanism for blockade of the pro-apoptotic effects of secreted gal-3
- findings suggest that Gal-3 may function as an immune regulator to inhibit T-cell immune responses and promote tumor growth, thus providing a new mechanism for tumor immune tolerance
- 90K (Mac-2 BP) may have a role in progression of node-negative breast cancer
- Data suggest that Galectin-3 plays an essential role during the acquisition of vasculogenic mimicry and angiogenic properties associated with melanoma progression.
- loss of galectin-3 appears to be involved in the carcinogenesis of transitional cell carcinoma of the urinary bladder
- Galectin has a role in cell migration in cultured lung and prostate cancer cells
- glomerular Gal-3 expression in renal tissue and serum Gal-3 levels were elevated in patients with SLE nephritis versus healthy controls; moreover, they reflected disease activity; Gal-3 might contribute to the inflammatory process in SLE
- Data implicate galectin-3 H(64) in breast cancer and explain, in part, the noted racial disparity.
- Gal-3 silencing with RNA interference stimulates apoptosis, while Gal-3 overexpression protects against both TRAIL- and doxorubicin-induced apoptosis in papillary thyroid cancer cells.
- Galectin-3 plays a role in human monocyte activation and adhesion in the presence of porcine aortic endothelial cells
- Results demonstrate that galectin-3 stabilizes hnRNP Q via complex formation, and reduction in the hnRNP Q level leads to slow proliferation and less susceptibility to 5-FU.